Background: Alveolar soft part sarcoma (ASPS) is a rare soft tissue tumor that typically affects young patients. Similar to other soft tissue sarcomas, it has high pulmonary metastasis ability, whereas compared with other soft tissue sarcomas, it has high brain metastasis ability. Because of the rarity of the disease, most studies on ASPS have been case reports and small series studies. Method: We performed a retrospective study to evaluate the clinical and pathological features and oncological results in a consecutive series of patients with localized or metastatic ASPS treated at our institute between 1994 and 2014. Demographics, location, severity of disease, treatment provided, progression-free survival, and overall survival were evaluated. Results: A total of 13 patients were investigated. The most common locations of primary tumor were the thigh (n ¼ 6, 47%), followed by the flank (n ¼ 3, 23%), forearm (n ¼ 2, 15%), and calf (n ¼ 2, 15%). Three patients were initially diagnosed as having hemangiomas elsewhere. These patients received unplanned intralesional excision. All the patients received wide tumor resection at our institute. Over the average followup period of 80.5 months (range: 36e133 months), the 5-year overall survival rate was 67.5%. Four patients were continuously disease free (31%), six were living with disease (46%), and three died of disease (23%). Of nine patients who presented with distant pulmonary metastasis, two had bony and brain metastases. The 5-year survival rate was 66.7% in patients who received chemotherapy and those who did not ( p ¼ 0.941). Conclusion: The treatment strategy for ASPS is wide resection, and postoperative chemotherapy may be crucial for long-term survival. In addition, this type of tumor has a high distant metastasis rate at the time of diagnosis, particularly in the lungs and brain.
Introduction
Alveolar soft part sarcoma (ASPS) is a rare, clinical, and distinctive soft tissue sarcoma that typically affects young patients and was initially described by Christopherson in 1952 . 1 It is generally believed to account for 0.5%e1% of all soft tissue tumors. 2, 3 ASPS typically occurs in adolescents and young adults aged 15e35 years, particularly in females, who exhibit an incidence rate of 60%. 4, 5 The location of the tumor is typically in the deep soft tissue, primarily in the thighs or buttocks; however, it is also found in the arms, breasts, genital area, chest, and retroperitoneal tissue. 6 Radiographically, ASPS is characterized by calcification through plain radiography. In addition, magnetic resonance imaging (MRI) has revealed high signals in both T1-and T2-weighted images and internal and external multilobulated signal changes (Fig. 1) . 7, 8 Histopathologically, periodic acid-Schiff-positive findings may reveal rhomboid-shaped crystalline material, and ASPS cells also have round, regularly placed nuclei with vesicular chromatin and a prominent central nucleolus (Fig. 2) . 9 Genetically, ASPS is caused by an unbalanced translocation, namely der(17)t(X:17)(p11;p25), which results in the formation of an ASPLeTFE3 fusion gene. 10 Because of the rarity of this disease, most studies on ASPS have been case reports and small series studies. In the present study, we first analyzed the patients' demographic and tumor characteristics in Taiwan. Second, we evaluated the factors related to clinical outcomes of ASPS.
Methods
The medical records of 23 patients pathologically diagnosed as having ASPS who received surgical treatment between June 1994 and July 2014 were analyzed in our hospital. Those treated at other departments (n ¼ 10) were excluded. Two patients were diagnosed as having ASPS in other areas such as the nasopharyngeal area (n ¼ 1) and retroperitoneal tissue (n ¼ 1). Eight were receiving chemotherapy without surgical intervention. No patients received the treatment protocol in our department. A total of 13 patients were enrolled in this study. The mean age of the patients was 21 years (range: 9e52 years). The mean follow-up period was 80.5 months (range: 36e133 months). We performed a retrospective study to evaluate the patients' demographic and tumor characteristics. In addition, the clinical outcomes were analyzed and compared based on several factors.
The anatomic location and depth of each tumor were evaluated and recorded by the first medical doctor. A tumor was classified as deep if it invaded the deep fascia in the imaging examinations performed before surgery. Tumor length, width, and depth were measured on preoperative MRI scans and tumor volume (V) was calculated using the cylinder formula. To identify pulmonary metastasis and local tumor recurrence, plain radiography and chest computed tomography (CT) were performed at the time of diagnosis, every 3 months for the first 2 years postsurgery, every 6 months in the third to fifth years postsurgery, and annually after the fifth year postsurgery. The presence of pulmonary metastasis and local recurrence was observed and recorded.
Of the 13 patients, three were initially diagnosed as having hemangiomas elsewhere and two initially received unplanned intralesional curettage. After transfer to our hospital, the three patients with hemangiomas elsewhere received wide tumor resection. The remaining 10 patients were preoperatively diagnosed as having ASPS in our hospital and received wide tumor excision. The excision margin was confirmed through microscopic examination as positive (tumor within 1 mm from the edge of excision) or negative (tumor not within 1 mm from the edge of excision) ( Table 1) .
The 5-year survival rate was estimated using the KaplaneMeier method. A p value of <0.05 was considered statistically significant, and all analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA).
Results

Patient demographics and tumor characteristics
Of the 13 patients, six were men and seven were women, and their mean age was 21 years (range: 9e52 years). Information on tumor size was available for all patients. The mean volume was 118.8 mL (range: 7.0e306.2 mL). The most common primary tumor locations were the thigh (n ¼ 6, 47%), followed by the flank (n ¼ 3, 23%), forearm (n ¼ 2, 15%), and calf (n ¼ 2, 15%).
Metastasis
Nine patients (69.2%) developed pulmonary metastasis. One of these patients also presented with brain metastasis and another presented with bone metastasis. Of these nine patients, five were male and four were female. Their mean age was 20.8 years (range: 11e52 years). To evaluate age, a cutoff point of 15 years was used to divide the patients into younger and older age groups. In the younger age group, 80% of the patients developed pulmonary metastasis, compared with only 62.5% in the older age group, and the difference was not statistically significant ( p ¼ 0.690). Furthermore, tumor location was not related to pulmonary metastasis ( Table 2 ). The mean tumor volume increased to 161.62 mL in patients with pulmonary metastasis, compared with 22.31 mL in patients without pulmonary metastasis ( p ¼ 0.016; Table 2 ). Based on a diameter of >5 cm as the cutoff point for tumor size, seven patients (87.5%) exhibited pulmonary metastasis in the large tumor group, whereas only 40% of the patients exhibited pulmonary metastasis in the small tumor group ( p ¼ 0.083; Table 2 ).
Timing of metastasis
Of the nine patients with pulmonary metastasis, five exhibited primary pulmonary metastasis (metastasis at initial diagnosis). The mean time span from initial diagnosis to occurrence of pulmonary metastasis was 28.8 months in the remaining three patients (Table 1) .
Chemotherapy and thoracotomy
Seven patients received chemotherapy with an alkylating agent (ifosfamide) and doxorubicin. Four patients received thoracotomies for metastatic pulmonary lesions. One patient (case 3) exhibited primary metastasis and underwent six thoracotomies. Two patients did not undergo thoracotomies for metastatic pulmonary lesions because of poor medication conditions (cases 9 and 10). One patient exhibited lesion regression during chemotherapy (case 13).
Radiotherapy
Two patients (cases 2 and 13) received local radiotherapy after wide excision. The first patient (case 2) without pulmonary metastasis had approximately 7 mL of tumor over the left forearm, and the other (case 13) with pulmonary metastasis had approximately 306.2 mL of tumor over the right buttock. After local radiotherapy, no local recurrence occurred.
Local recurrence
Of three patients who had local recurrence after wide excision, one (case 9) initially received unplanned intralesional curettage at another hospital and subsequently received wide excision at out institute. However, the tumor recurred 6 months after wide excision. The other two patients (cases 3 and 10) received wide excision after receiving a diagnosis of ASPS at our hospital. Local recurrence occurred at 9 and 13 months postsurgery, respectively. Two patients (cases 9 and 10) died 53 and 36 months after wide excision, respectively.
Survival rate
The 5-year overall survival rate of the 13 patients was 67.5% (Fig. 3A) . The 5-year survival rate for patients without pulmonary metastasis was 100%, compared with only 51.4% for patients with pulmonary metastasis. However, the difference was not statistically significant ( p ¼ 0.184; Fig. 3B ). The 5-year survival rate of patients who underwent chemotherapy and those who did not was 66.7% ( p ¼ 0.941; Fig. 3C ). 16 demonstrated the ultrastructural appearance of ASPS with intracytoplasmic crystals. ASPS is a rare disease that accounts for <1% of all soft tissue tumors. 2, 3, 12 The most common invasive locations are the thighs and buttocks. 6 ASPS primarily affects adolescents and young adults. 4, 5 A slight female preponderance is observed in patients aged 30 years. 13 In our study, the number of female patients was almost identical to that of male patients (F/M ¼ 6/7).
Discussion
ASPS exhibits slow-growth characteristics but has a high metastatic rate at the time of diagnosis of 20%e40% . 11 The lungs are the most frequent sites of metastasis through the hematogenous route, followed by the brain and bones. 6 In one study, the incidence of brain metastasis due to ASPS was Table 1 Patient profiles and outcomes.
No. reported to be approximately 30%, and the survival rate was low (median survival of 12 months) after diagnoses of brain metastasis. 13 Nine patients (69.2%) developed pulmonary metastasis in our study; one of these patients also had brain metastasis (7.7%) and another also had bone metastasis (7.7%). The prognoses of chemotherapy were poor for those with brain metastasis because of the failure of several chemotherapeutic agents to cross the bloodebrain barrier. 24 One patient with brain metastasis in our study received Gamma Knife treatment, but died 60 months later.
Radiologically, the plane view may reveal soft tissue calcification. ASPS exhibits hypervascular lesions on contrastenhanced CT or angiography with a dense tumor stain and tortuous, dilated draining veins. 8, 9 Because of the hypervascular lesions, making differential diagnoses of hemangioma, arteriovenous malformation, clear-cell sarcoma, metastatic malignant melanoma, and other soft tissue sarcomas with internal bleeding is critical. MRI typically reveals a high signal intensity on T1-and T2-weighted images, and contrast-enhanced MRI reveals multiple peritumoral and intratumoral tortuous signal voids and intense enhancement. 8, 9, 14, 15 In our study, three patients were initially diagnosed as having hemangiomas. Two of these patients (cases 4 and 9) underwent unplanned surgery elsewhere. Subsequently, after rewide excision at our hospital and postoperative chemotherapy, one of them (case 4) was alive with disease status (pulmonary metastasis) after 133 months of follow-up.
Studies have reported that the 5-year overall survival is rate is 52.6%e88% for ASPS (Table 3) and that several factors are related to the outcomes, such as the stage, size, and surgical margin. 13,17e20 Ogura et al. 13 reported a 5-year survival rate of 64% of a patient cohort after surgical resection of ASPS, suggesting that tumor size and American Joint Committee on Cancer stage are related to disease progression. Cho et al. 20 reported that the long-term survival rate was higher in patients with tumors 50 mm in diameter than in those with tumors >50 mm in diameter. Ogose et al. 21 reported that the 5-and 10-year survival rates in patients with tumors <50 mm in diameter were 72% and 65%, respectively, whereas those in patients with a tumors >50 mm in diameter were 46% and 9%, respectively. Other studies have reported that a larger tumor size indicates a higher incidence of organic metastasis. 22, 23 Based on tumor size, the survival rate was 89% in patients with tumors <50 mm in diameter and 50% in patients with Fig. 3 . KaplaneMeier modeling for the 5-year survival rates of (A) all 13 ASPS patients, (B) patients with ASPS with or without pulmonary metastasis, and (C) patients with ASPS who did and did not receive chemotherapy. 19 reported that the quality of surgery is basically related to the prognosis of ASPS and demonstrated a 10-year survival rate of 53.4%. Lieberman et al. 3 suggested that if residual tumor cells are still observed over the surgical margin according to pathological reports, the recurrence rate of ASPS is >20%, and thus patients would require more aggressive treatments after surgery. In our series, all the pathological reports revealed negative surgical margins. Sherman et al. 27 suggested that radiation therapy may play a beneficial role in enhancing the local control of limited surgery for ASPS.
The local recurrence rate of ASPS ranges from 11% to 50%. 24, 25 In our study, all the patients received wide-margin resection, and the local recurrence rate was 23% (3/13). The survival rate of patients without local recurrence was 90% (9/ 10), whereas that of patients with local recurrence was 33% (1/ 3). Two patients (cases 2 and 13) received local radiotherapy after wide excision, and no local recurrence was observed over the surgical site.
No studies have reported significant survival benefits for patients undergoing adjuvant chemotherapy after surgery. 3, 26, 28, 29 Reichardt et al. 29 analyzed 68 patients who received chemotherapy with drugs such as anthracyclines and ifosfamide and demonstrated complete remission in 4%, partial remission in 3%, stable disease in 41%, and progressive disease in 51% of the patients. In our study, six patients received chemotherapy with an alkylating agent (ifosfamide) and an antibiotic agent (doxorubicin), and the results revealed partial remission in 16.7% (1/6), stable disease in 50% (3/6), and death in 33.3% (2/6) of the patients.
The demographics and tumor characteristics of the patients in the present study were similar to those in other studies. The factors that affect clinical outcomes included large tumor size and distant metastasis. The treatment strategy for ASPS is wide resection, and postoperative chemotherapy may be crucial for long-term survival. Because of the radiological presentation, differential diagnoses of ASPS should be considered while treating hemangiomas.
